

Pediatric Kidney-Pancreas Transplant Recipient Registration Worksheet

The revised worksheet sample is for reference purposes only and is pending OMB approval.

Note: These worksheets are provided to function as a guide to what data will be required in the online TIEDI^B. application. Currently in the worksheet, a red asterisk is displayed by fields that are required, independent of what other data may be provided. Based on data provided through the online TIEDI^B. application, additional fields that are dependent on responses provided in these required fields may become required as well. However, since those fields are not required in every case, they are not marked with a red asterisk.

Recipient Information	
Name:	DOB:
SSN:	Gender:
HIC:	Tx Date:
State of Permanent Residence: *	
Permanent Zip: *	-
Provider Information	
Recipient Center:	
Surgeon Name: *	
NPI: *	
Donor Information	
UNOS Donor ID #:	
Donor Type:	
Patient Status	
Kidney Primary Diagnosis: *	
Specify:	
Pancreas Primary Diagnosis: *	
Specify:	
Date: Last Seen, Retransplanted or Death *	
	LIVING
Patient Status: *	© DEAD
	© RETRANSPLANTED
	* RETRANSFEANTED
Retransplanted organ:	
Primary Cause of Doath	
Primary Cause of Death:	
Specify:	
Contributory Cause of Death:	

Specify:	
Contributory Cause of Death:	
Specify:	
Transplant Hospitalization:	
Date of Admission to Tx Center: *	
Date of Discharge from Tx Center:	
Was patient hospitalized during the last 90 days prior to the transplant admission:	C YES O NO UNK
	IN INTENSIVE CARE UNIT
Medical Condition: *	HOSPITALIZED NOT IN ICU
	O NOT HOSPITALIZED
Functional Status: *	
Cognitive Development: *	Definite Cognitive delay/impairment (verified by IQ score <70 or unambiguous behavioral observation) Probable Cognitive delay/impairment (not verified or unambiguous but more likely than not, based on behavioral observation or other evidence) Questionable Cognitive delay/impairment (not judged to be more likely than not, but with some indication of cognitive delay/impairment such as expressive/receptive language and/or learning difficulties) No Cognitive delay/impairment (no obvious indicators of cognitive delay/impairment) Not Assessed
Motor Development: *	 Definite Motor delay/impairment (verified by physical exam or unambiguous behavioral observation) Probable Motor delay/impairment (not verified or unambiguous but more likely than not, based on behavioral observation or other evidence) Questionable Motor delay/impairment (not judged to be more likely than not, but with some indications of motor delay/impairment) No Motor delay/impairment (no obvious indicators of motor delay/impairment) Not Assessed
Academic Activity Level: ★	 Full academic load Reduced academic load Unable to participate in academics due to disease or condition Unable to participate regularly in academics due to dialysis

		Not Applicable < 5 Status Unknown	years old/ Hig	h School graduate	
Kidney Source of Payment:					
Primary: *					
Specify:					
Secondary:					
Pancreas Source of Payment:					
Primary: *					
Specify:					
Secondary:					
Clinical Information : PRETRANSPLA	NT				
Date of Measurement: *					
Height: *		ft. in.	cm %ile	ST=	
Weight: *			kg %ile	ST=	
BMI:	kg/m ²		%ile		
Growth hormone therapy as a marker for delay: * Previous Transplants:	growth	C YES O NO O U	NK		
Previous Transplant Organ	Previous Tra	nsplant Date	Previous T	ransplant Graft Fail Date	
The three most recent transplants are listed 978-4334 or by emailing unethelpdesk@unethelpdesk@unethelpdesk	I here. Please co os.org.	ontact the UNet Help Desk to	confirm more	than three previous transpl	ants by calling 800-
Pretransplant Dialysis: *		C YES O NO O U	NK		
If Yes, Date First Dialyzed:			ST=	:	
Average Daily Insulin Units: *			ST=	:	
Attorage Daily mount office.					
Serum Creatinine at Time of Tx: *		r	ng/dl ST =	:	
		r		:	
Serum Creatinine at Time of Tx: *		Positive		:	
Serum Creatinine at Time of Tx: * Viral Detection:				:	
Serum Creatinine at Time of Tx: *		Positive		:	
Serum Creatinine at Time of Tx: * Viral Detection:		Positive Negative	ng/dl ST =	:	
Serum Creatinine at Time of Tx: * Viral Detection:		Positive Negative Not Done	ng/dl ST =		

CMV IgG: ★	Not Done
	UNK/Cannot Disclose
	C Positive
CMV IgM: ★	○ Negative
Civi v Igivi. ••	Not Done
	UNK/Cannot Disclose
	Positive
HBV Core Antibody: ★	○ Negative
TIBV Core Antibody. "	Not Done
	UNK/Cannot Disclose
	Positive
HBV Surface Antigen: ★	○ Negative
TIBV Surface Affiligen. •••	Not Done
	UNK/Cannot Disclose
	Positive
HCV Serostatus: ★	○ Negative
nov Selusidius.	O Not Done
	UNK/Cannot Disclose
	C Positive
EBV Serostatus: ★	○ Negative
LBV Selosialus. **	Not Done
	UNK/Cannot Disclose
Was preimplantation kidney biopsy performed at the transplant center:	C YES NO
Did patient receive any pretransplant blood tranfusions: ★	C YES NO UNK
Any tolerance induction technique used:	C YES NO UNK
	O NO PREVIOUS PREGNANCY
	1 PREVIOUS PREGNANCY
	2 PREVIOUS PREGNANCIES

	3 PREVIOUS PREGNANCIES			
	6 4 PREVIOUS PREGNANCIES			
Basilian Basilian	5 PREVIOUS PREGNANCIES			
Previous Pregnancies:	MORE THAN 5 PREVIOUS PREGNANCIES			
	O NOT APPLICABLE: < 10 years old			
	UNKNOWN			
Malignancies between listing and transplant: *	C YES O NO UNK			
This question is NOT applicable for patients receiving living	donor transplants who were never on the waiting list.			
	Skin Melanoma			
	Skin Non-Melanoma			
	CNS Tumor			
	Genitourinary			
	Breast			
If yes, specify type:	Thyroid			
	Tongue/Throat/Larynx			
	Lung			
	Leukemia/Lymphoma			
	Liver			
	Other, specify			
Specify:				
Is growth hormone therapy used between listing and transplant: *	C YES NO UNK			
Bone Disease (check all that apply):				
Fracture between listing and transplant: *	C YES ONO UNK			
	Spine-compression # of fractures:			
Specify Location and number of fractures: *	Extremity # of fractures:			
	Other # of fractures:			
AVN (avascular necrosis): *	C YES ONO UNK			
Clinical Information : TRANSPLANT PROCEDURE				
Multiple Organ Recipient				
Were extra vessels used in the transplant procedure:				
Vessel Donor ID:				

Procedure Type:	
Surgical Information:	
	© Before
Was the Pancreas revascularized before or after other	Simultaneous
organs:	← After
	Not Applicable
	C Iliac Fossa PA left/KI right
	☐ Iliac Fossa PA right/KI left
Surgical Incision:	C Left
	Midline
	Right
	○ INTRA-PERITONEAL
Graft Placement: ★	© RETRO-PERITONEAL
	PARTIAL INTRA/RETRO-PERITONEAL
	Simultaneous Kidney-Pancreas
Operative Technique: *	Cluster
	Multi-Organ Non-Cluster
	ENTERIC W/ROUX-EN-Y
	ENTERIC W/O ROUX-EN-Y
Durt Management &	CYSTOSTOMY
Duct Management: ★	O DUCT INJECTION IMMEDIATE
	DUCT INJECTION DELAYED
	OTHER SPECIFY
Specify:	
	SYSTEMIC SYSTEM (ILIAC:CAVA)
Venous Vascular Management: ★	PORTAL SYSTEM (PORTAL OR TRIBUTARIES)
	NA/Multi-organ cluster
	CELIAC WITH PANCREAS
	Y-GRAFT TO SPA & SMA
Arterial Reconstruction: ★	SPA TO SMA DIRECT
	SPA TO SMA WITH INTERPOSITION

Specify: Venous Extension Graft: ★	© SPA ALONE © OTHER SPECIFY © YES © NO
Kidney and Pancreas Preservation Information:	
Total Cold ischemia Time Right KI(OR EN-BLOC): (if pumped, include pump time): *	hrs ST=
Total Warm Ischemia Time Right KI (OR EN-BLOC): (Include Anastomotic time):	min ST:
Total Cold Ischemia Time Left KI (If pumped, include pump time): ★	hrs ST=
Total Warm ischemia Time Left KI (Include Anastomotic time):	min ST=
Total Pancreas Preservation Time (include Cold, Warm, Anastomotic time): ★	hrs ST=
Kidney(s) received on: ★	© Pump
	€ N/A
Received on ice:	Stayed on ice Put on pump
Received on pump:	Stayed on pump Put on ice
If put on pump or stayed on pump:	
Final resistance at transplant:	ST=
Final flow rate at transplant:	ST=
Incidental Tumor found at time of Transplant:	© YES © NO © UNK
	Oncocytoma
	Renal Cell Carcinoma
If yes, specify tumor type:	Carcinoid
	C Adenoma
	Transitional Cell Carcinoma
	Other Primary Kidney Tumor, Specify.
Specify:	

Clinical Information : POST TRANSPLANT	
Kidney Graft Status: *	Functioning Failed
If death is indicated for the recipient, and the death was a res	ult of some other factor unrelated to graft failure, select Functioning.
Resumed Maintenance Dialysis:	C YES C NO
Date Maintenance Dialysis Resumed:	
Select a Dialysis Provider:	
Provider #:	
Provider Name:	
Kidney Date of Graft Failure:	
	HYPERACUTE REJECTION
	C ACUTE REJECTION
	PRIMARY FAILURE
	GRAFT THROMBOSIS
Kidney Primary Cause of Graft Failure:	INFECTION
	SURGICAL COMPLICATIONS
	UROLOGICAL COMPLICATIONS
	RECURRENT DISEASE
	OTHER SPECIFY CAUSE
0 "	- CITER OF EOIL FORGE
Specify:	
Contributory causes of graft failure:	
Kidney Acute Rejection:	C YES O NO UNK
Kidney Graft Thrombosis:	C YES NO UNK
Kidney Infection:	C YES NO UNK
Surgical Complications:	C YES NO UNK
Urological Complications:	C YES NO UNK
Recurrent Disease:	C YES NO UNK
Other, Specify:	
Did patient have any acute kidney rejection episodes	Yes, at least one episode treated with anti-rejection agent
between transplant and discharge: *	Yes, none treated with additional anti-rejection agent
	○ No
	Biopsy not done

	Yes, rejection confirmed
Was biopsy done to confirm acute rejection:	Yes, rejection not confirmed
Most Recent Serum Creatinine Prior to Discharge: ★	mg/dl ST=
Kidney Produced > 40ml of Urine in First 24 Hours:	C YES C NO
Patient Need Dialysis within First Week: *	C YES C NO
Creatinine Decline by 25% or More in First 24 Hours on 2 separate samples:	© YES © NO
Pancreas Graft Status: *	Functioning Partial Function Failed
If death is indicated for the recipient, and the death was a resi	ult of some other factor unrelated to graft failure, select Functioning.
	☐ Insulin
Method of blood sugar control: (check all that	Oral medication
apply)	Diet
	No Treatment
Date Insulin/Medication Resumed:	
Date of Graft Failure Pancreas:	
Pancreas Graft Removed:	C YES ONO UNK
If Yes, Date Pancreas Graft Removed:	
Pancreas Primary Cause of Graft Failure:	
Pancreas Primary Cause of Graft Failure/Specify:	
Contributory causes of graft failure:	
Pancreas Graft/Vascular Thrombosis:	C YES NO UNK
Pancreas Infection:	C YES ONO UNK
Bleeding:	G YES G NO G UNK
Anastomotic Leak:	C YES O NO C UNK
Hyperacute Rejection:	C YES NO UNK
Pancreas Acute Rejection:	G YES G NO G UNK
Biopsy Proven Isletitis:	© YES © NO © UNK
Pancreatitis:	G YES G NO G UNK
Other, Specify:	

Did patient have any acute pancreas rejection episodes between transplant and discharge: ★	Yes, at least one episode treated with anti-rejection agent Yes, none treated with additional anti-rejection agent No
Was biopsy done to confirm acute rejection:	Biopsy not doneYes, rejection confirmedYes, rejection not confirmed
Pancreas Transplant Complications: (Not leading to graft failure.)	
Pancreatitis: *	C YES O NO C UNK
Anastomotic Leak: *	C YES O NO UNK
Abcess or Local Infection: *	C YES ONO UNK
Other:	
Weight Post Transplant: ★	lbs. kg ST=
Treatment	
Biological or Anti-viral Therapy:	C YES NO Unknown/Cannot disclose
	Acyclovir (Zovirax)
	Cytogam (CMV)
	Gamimune
	☐ Gammagard
	Ganciclovir (Cytovene)
If Yes, check all that apply:	☐ Valgancyclovir (Valcyte)
	HBIG (Hepatitis B Immune Globulin)
	Flu Vaccine (Influenza Virus)
	☐ Lamivudine (Epivir) (for treatment of Hepatitis B)
	Other, Specify
	Valacyclovir (Valtrex)
Specify:	
Specify:	
Other therapies:	C YES O NO

If Yes, check all that apply:	☐ Photopheresis☐ Plasmapheresis☐ Total Lymphoid Irradiation	(TLI)	
Immunosuppressive Information			
Are any medications given currently for maintenance or anti-rejection: *	C YES NO		
Did the patient participate in any clinical research protocol for immunosuppressive medications:	C YES NO		
If Yes, Specify:			
Immunosuppressive Medications			
View Immunosuppressive Medications			
Definitions Of Immunosuppressive Medications			
For each of the immunosuppressive medications listed, sele that were prescribed for the recipient during the initial transpassociated box(es) blank.			
Induction (Ind) immunosuppression includes all medication acute rejection. Though the drugs may be continued after di immunosuppressive maintenance. Induction agents are usu. Atgam, Thymoglobulin, OKT3, Simulect, or Zenapax). Some recorded as rejection therapy if used for this reason. For eac administered in the space provided. For example, if Simulect 2, even if the second dose was given after the patient was definition and the second dose.	scharge for the first 30 days after transly polyclonal, monoclonal, or IL-2 reset these drugs might be used for anoth induction medication indicated, write or Zenapax was given in 2 doses a discharged.	nsplant, it will not be used be ceptor antibodies (example other finite period for rejecte the total number of days week apart, then the total	ong-term for e: Methylprednisolone, tion therapy and would be s the drug was actually number of days would be
Maintenance (Maint) includes all immunosuppressive medieither long-term or intermediate term with a tapering of the cdrug (example: Prednisone, Cyclosporine, Tacrolimus, Myccimmunosuppressive medications given to treat rejection epis	dosage until the drug is either elimina ophenolate Mofetil, Azathioprine, or R	ted or replaced by another	long-term maintenance
Anti-rejection (AR) immunosuppression includes all immun during the initial post-transplant period or during a specific for Methylprednisolone, Atgam, OKT3, or Thymoglobulin). Whe Mycophenolate Mofetil to Azathioprine) because of rejection maintenance immunosuppression.	ollow-up period, usually up to 30 days in switching maintenance drugs (exar	s after the diagnosis of acu nple: from Tacrolimus to C	te rejection (example: yclosporine; or from
If an immunosuppressive medication other than those listed Other Immunosuppressive Medication field, and enter the fu medications.			
	Ind.	Days	ST
Steroids (Prednisone,Methylprednisolone,Solumedrol,Medrol,Decadr	ron)		
Atgam (ATG)			
OKT3 (Orthoclone, Muromonab)			
Thymoglobulin			
Simulect - Basiliximab			
Zenapax - Daclizumab			

Azathioprine (AZA, Imuran)			
EON (Generic Cyclosporine)			
Gengraf (Abbott Cyclosporine)			
Other generic Cyclosporine, specify brand:			
Neoral (CyA-NOF)			
Sandimmune (Cyclosporine A)			
Mycophenolate Mofetil (MMF, Cellcept, RS61443)			
Tacrolimus (Prograf, FK506)			
Modified Release Tacrolimus FK506E (MR4)			
Sirolimus (RAPA, Rapamycin, Rapamune)			
Myfortic (Mycophenolate Sodium)			
Other Immunosuppressive Medications			
Other Immunosuppressive Medications	Ind. Days	ST	Maint AR
Other Immunosuppressive Medications Campath - Alemtuzumab (anti-CD52)	Ind. Days	ST	Maint AR
	_	ST	
Campath - Alemtuzumab (anti-CD52)		ST	
Campath - Alemtuzumab (anti-CD52) Cyclophosphamide (Cytoxan)		ST	
Campath - Alemtuzumab (anti-CD52) Cyclophosphamide (Cytoxan) Leflunomide (LFL, Arava) Methotrexate (Folex, PFS, Mexate-AQ,		ST	
Campath - Alemtuzumab (anti-CD52) Cyclophosphamide (Cytoxan) Leflunomide (LFL, Arava) Methotrexate (Folex, PFS, Mexate-AQ, Rheumatrex)		ST	
Campath - Alemtuzumab (anti-CD52) Cyclophosphamide (Cytoxan) Leflunomide (LFL, Arava) Methotrexate (Folex, PFS, Mexate-AQ, Rheumatrex) Other Immunosuppressive Medication, Specify		ST	
Campath - Alemtuzumab (anti-CD52) Cyclophosphamide (Cytoxan) Leflunomide (LFL, Arava) Methotrexate (Folex, PFS, Mexate-AQ, Rheumatrex) Other Immunosuppressive Medication, Specify Other Immunosuppressive Medication, Specify Rituximab		ST	
Campath - Alemtuzumab (anti-CD52) Cyclophosphamide (Cytoxan) Leflunomide (LFL, Arava) Methotrexate (Folex, PFS, Mexate-AQ, Rheumatrex) Other Immunosuppressive Medication, Specify Other Immunosuppressive Medication, Specify		ST	
Campath - Alemtuzumab (anti-CD52) Cyclophosphamide (Cytoxan) Leflunomide (LFL, Arava) Methotrexate (Folex, PFS, Mexate-AQ, Rheumatrex) Other Immunosuppressive Medication, Specify Other Immunosuppressive Medication, Specify Rituximab			

FTY 720	
Other, Specify	
UNOS View Only	
Comments:	